Emcure Pharmaceuticals has announced its consolidated financial results for the fourth quarter and full year ended March 31, 2026, reporting revenue growth of 16.7% in Q4 and 16.6% for FY26. The company said full-year revenue crossed the US$ 1 billion milestone, based on the average USD-INR exchange rate of 88.29, while adjusted PAT grew 36.0% in Q4 and 40.9% for the year.
For FY26, revenue from operations stood at ₹9,204 crore, up from ₹7,896 crore in FY25, while EBITDA rose 21.8% to ₹1,789 crore with margins of 19.4%. Reported PAT came in at ₹941 crore, up 33.1% year-on-year, and adjusted PAT reached ₹1,008 crore.
In Q4 FY26, revenue from operations increased to ₹2,470 crore from ₹2,116 crore in the same quarter last year. EBITDA improved 24.5% to ₹485 crore, reported PAT rose 23.6% to ₹244 crore, and adjusted PAT climbed 36.0% to ₹279 crore.
Satish Mehta, CEO and Managing Director of Emcure Pharmaceuticals, said FY26 was the first year of the company’s five-year strategic plan and reflected strong execution across both domestic and international businesses. He added that the company expanded through in-licensing, the Zuventus minority buyout, and bolt-on acquisitions in the UK and Canada, while its R&D pipeline in complex injectables and biosimilars remains a key future driver.
Domestic sales for FY26 grew 10.0% to ₹4,027 crore, led by cardiac, CNS and oncology products, while international sales rose 22.2% to ₹5,177 crore. In Q4, domestic sales increased 5.2% to ₹977 crore and international sales surged 25.7% to ₹1,493 crore.
